approaching patients with mf who are ineligible for sct
Published 2 weeks ago • 21 plays • Length 1:20Download video MP4
Download video MP3
Similar videos
-
2:23
factors to consider when selecting jak inhibitors for patients with mf
-
4:48
an insight into the management of cytopenias in mf
-
1:36
the role of molecular markers in patient selection for transplantation in myelofibrosis
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
2:13
exciting agents and treatment approaches emerging in the field of myelofibrosis
-
3:25
identifying & monitoring patients with high-risk clonal hematopoiesis
-
1:13
selecting conditioning regimens for patients with myelofibrosis undergoing allosct
-
1:05
approaching patients with penta-refractory myeloma: the importance of clinical trials
-
1:30
approaching patients with pv after treatment failure
-
2:07
the clearance of driver mutations following allosct impacts myelofibrosis disease outcomes
-
1:43
reasons why there are fewer treatment options for mds patients and hope for the future
-
2:42
which tests do you need before deciding on an aml treatment path?
-
1:05
using machine learning to predict the outcomes of patients with ndmm being treated with vrd
-
0:45
difference between quality of life & patient-reported outcomes
-
1:56
incorporating novel agents for myelofibrosis in the pre- and post-transplant settings
-
1:17
evaluating response to treatment in patients with emd
-
3:14
optimize your first visit with your aml team
-
1:53
parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib
-
2:12
the regulation of personalized medicine trials